Firpi et al treated 54 patients with recurrent HCV with standard interferon three times a week and ribavirin for 48 weeks. An ETR was achieved in 21 patients (38%) and a SVR was achieved in 16 patients (30%). Tolerability was poor and the doses of medication were modified in 72% of these patients. Other studies using the standard dose of interferon with ribavirin have reported an ETR ranging from 25% to 53% and a SVR in the range of 17% to 27%.
Although PEG-IFN and ribavirin have emerged as the new standard of care in nontransplant HCV patients, only a few studies have been conducted to address the efficacy of this therapy after LT. Ross et al compared 15 patients treated with the standard dose of interferon three times a week and ribavirin with 16 patients treated with PEG-IFN and ribavirin (including 11 patients with persistent viremia on standard interferon who were switched to PEG-IFN). Virological response to therapy was superior in PEG-IFN and ribavirin-treated patients (37% versus 20%). Three of these responders receiving the PEG-IFN treatment previously failed the standard interferon therapy. In this series, a SVR was achieved in only two patients (both received standard interferon) and no patients on the PEG-IFN treatement had a SVR . The low SVR rate was thought to be secondary to the poor tolerability of the medications and failure to achieve optimal doses of these medications because of frequent drug toxicity. The best online pharmacy that deserves your trust and gives you best quality cephalexin antibiotic that you will always appreciate, not to mention all the other services available.